Willie Earley, MD

Efficacy of Cariprazine in Patient Subgroups: Post Hoc Analysis of 3 Randomized, Placebo-Controlled Trials in Patients With Bipolar Depression

Introduction: Cariprazine is a dopamine D3-preferring D3/D2 and serotonin 5-HT1A receptor partial agonist approved to treat bipolar depression. The efficacy of cariprazine in patients wit...

Vladimir Maletic , MD;

Lakshmi Yatham , MBBS, FRCPC, MRCP, MBA;

Rakesh Jain , MD, MPH, RD;

Willie Earley , MD;

Mehul Patel , MD, PharmD;

Mauricio Tohen , MD, DrPH, MBA;

10/08/2020

Efficacy (NNT) and Tolerability (NNH) of Cariprazine in Bipolar Disorder

Background: Cariprazine is approved to treat manic, mixed, and depressive symptoms of bipolar I disorder. This analysis describes the efficacy and tolerability of cariprazine in bipolar I...

Willie Earley , MD;

Mehul Patel , MD, PharmD;

Mauricio Tohen , MD, DrPH, MBA;

Leslie Citrome , MD;

11/22/2019

Effects of Cariprazine on Prolactin Levels in Patients With Bipolar I Disorder

Background: Antipsychotic treatment has been linked to hyperprolactinemia, which can lead to increased nonadherence and changes in sexual hormones in both men and women. Here, we evaluate...

Mehul Patel , MD, PharmD;

Larry Culpepper , MD;

Deanna Kelly ;

Eduard Vieta , MD, PhD;

Thais Moreira , PharmD, PhD;

Willie Earley , MD;

11/22/2019

Cariprazine for Bipolar I Depression: A Randomized Double-Blind Placebo-Controlled Trial

Depressive episodes in bipolar I disorder (BP-1) are associated with increased disability, morbidity, and suicide, and have fewer evidence-based treatment options compared to manic episod...

Trisha Suppes , MD, PhD;

Mauricio Tohen , MD, DrPH, MBA;

Joseph Calabrese , MD;

Willie Earley , MD;

Maria Burgess , MD;

Barbara Khan , MS;

Ludmyla Rekeda , PhD;

Mehul Patel , MD, PharmD;

03/01/2019